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HIV transmission from mother to child – HAART compared 
with dual therapy
Gerhard Theron, Myrthe Nellensteijn, Anneke Theron, Jeanne Louw
To the Editor: There are increasing calls for the use of highly 
active antiretroviral therapy (HAART) for the prevention of 
perinatal mother-to-child transmission (PMTCT) of HIV.1 This 
approach does not recognise the weaknesses in health systems 
to implement complex treatment protocols. In addition, the 
safety of HAART during pregnancy is uncertain and the 
consequences of stopping HAART if not required outside 
pregnancy are unknown. If the same PMTCT of HIV could 
be attained with a simple regimen with proven safety and 
known adverse drug effects, this would be a better option in 
most under-resourced countries.2 The superiority of HAART 
compared with dual therapy according to World Health 
Organization (WHO) recommendations for immune-competent 
women to reduce PMTCT has not been proven.3
We aimed to determine whether there is a difference in 
perinatal HIV transmission on HAART therapy compared with 
the national dual-therapy regimen. In addition, the relation 
between CD4 counts and transmission in the dual-therapy 
group was investigated.
Method
A retrospective case control study was conducted. Files of 
all HIV-positive women with Delft and Mfuleni addresses, 
who delivered at Tygerberg Hospital (TBH) between January 
2007 and April 2008, were obtained after discharge. The 
antiretroviral treatment, which could be either HAART or dual 
therapy, received during pregnancy was recorded, along with 
the date when dual therapy was commenced. HAART was 
only commenced if the CD4 count was <250 cells/µl and the 
gestational age <34 weeks according to the provincial PMTCT 
guideline used during the study period.4 The first-line HAART 
regimen consists of stavudine (d4T), lamivudine (3TC) and 
nevirapine (NVP).4,5 Adequate dual therapy was at least 2 
weeks of antenatal zidovudine (AZT), intrapartum single-dose 
(sd) NVP and AZT (300 mg 3-hourly per mouth) as well as sd 
NVP and AZT for 1 week for the newborn baby.4 The first CD4 
count available was recorded and broken down into <250 and 
>250 cells/µl. Information regarding the type of delivery and 
the mother’s infant feeding choice was also recorded. Babies 
of HIV-positive mothers were tested for HIV with DNA PCR 
(polymerase chain reaction) tests at 14 weeks of age.4 Fisher’s 
exact test was done to determine whether the difference in 
transmission between the two groups was significant. The 
study was approved by the ethics committee of the Faculty of 
Health Sciences.
Results
A total of 581 HIV-positive women from the defined 
geographical area delivered babies during the study period. 
The study group included 73 women on HAART; 508 women 
received dual therapy; of the latter, 257 (50.6%) were eligible 
because their dual therapy was regarded as adequate. A 
control group of 146 patients was randomly selected from the 
adequate dual therapy group. Of the study group, 62 babies 
were available for follow-up; 58 (80.8%) had PCRs, 4 mothers 
declined PCRs, and 11 (15.1%) babies could not be traced. 
In the control group, 124 newborn babies were available for 
follow-up; 119 (81.1%) had PCRs, 5 mothers declined PCRs, 
and 22 (15.1%) babies could not be traced.
The difference in transmission rates in the study (2/58 
(3.4%)) and control groups (12/119 (10.1%)) is not significant 
(p=0.15). The CD4 count in the study group was <250 cells/µl 
in 56 women (76.7%) and >250 cells/µl in 17. Both women 
who transmitted HIV to their babies were in the <250 cells/µl 
group. In the control group, the CD4 count distribution is 
shown in Table I. The transmission rate of women (Table I) 
with a CD4 count >250 cells/µl was 6/98 (6.1%) and, if the 
CD4 count was <250 cells/µl, the transmission rate was 6/21 
(28.6%). Transmission rates in the control group according 
to three CD4 count cut-off values are shown in Table I. The 
caesarean section rate in the study group was 32.9% (31/73), 
with 7 elective caesarean sections. In the control group, the rate 
was 33.3% (56/146) with 8 elective caesarean sections. There 
was no significant difference regarding elective caesarean 
sections between the two groups (p=0.3). One mother in 
the study group, and 3 mothers in the control group, chose 
exclusive breastfeeding. No information about infant feeding 
was available for 2 mothers in the study group and 1 in the 
control group. All the other mothers went home formula-
feeding their babies.
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Discussion
The study was confined to two high-prevalence geographical 
areas whose clinics send their PCR tests on babies to the 
virology laboratory at the Faculty of Health Sciences at TBH. 
The numbers are small and the results need to be interpreted 
with the necessary caution. The provincial protocol used a 
CD4 cut-off for HAART of <200 cells/µl. This was changed to 
<250 cells/µl in October 2006 by clinicians working at TBH.4 
The proportion of women in the dual-therapy group with 
adequate therapy (50.6%) compares favourably with what was 
achieved with the PMTCT programme in the public health 
sector in Thailand (61.7%).6 More strict criteria were applied 
for adequate dual therapy (at least 2 weeks of antenatal 
AZT) in the index study, according to the recommendation 
of the provincial health authority. The proportion of babies 
whose information was available for transmission rates to be 
determined (80.8% and 81.1% in the study and control group, 
respectively) is also in accordance with what was found in 
Thailand (75.8%).6 Invariably, a proportion of women with 
CD4 counts of <250 cells/µl will be on dual therapy. The 
most common reasons are CD4 count results available with 
a gestational age >34 weeks (too late to commence HAART, 
according to the 2003 provincial PMTCT protocol), missing 
appointments at the ARV clinic, defaulting antenatal visits, 
first contact with health care when in labour, and failing the 
adherence programme.4,7
The high transmission rate (10.1%) in the adequate dual-
therapy group is due to a very high transmission rate in the 
group, with a CD4 count <250 cells/µl (28.6%). A CD4 count of 
<250 cells/µl seems to be a reasonable cut-off for initiation of 
HAART as the transmission rates at higher counts do not 
improve markedly (Table I). The proportion of women who 
will require HAART with a CD4 cut-off of <350 cells/µl will be 
more than doubled in the adequate dual-therapy group (14.6 - 
36.1%). This is important information to consider as the WHO 
suggests a 350 CD4 cut-off for HAART, and some countries in 
southern Africa are using the higher CD4 cut-off for 
commencing HAART.1 Early first attendance at antenatal 
clinics is very important. CD4 counts of HIV-positive women 
need to be available within 1 week. Every effort should be 
made to initiate HAART if the CD4 count is <250 cells/µl. 
Earlier PCRs at 6 weeks according to the new policy and 
guidelines for the implementation of the PMTCT programme 
of the national Department of Health will improve baby 
follow-up.5 A larger study is required to determine whether 
HAART and dual therapy have an equivalent transmission rate 
at a higher CD4 count cut-off than 250 cells/µl.
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Table I. Transmission rate in the dual-therapy group according to various CD4 count (cells/µl) cut-off values
CD4 group*          N (%)       Tested PCR yes (%)          Positives             Transmission rates (%)
<250           21 (14.6)       21 (100)                6              28.6
≥250         123        98   (78)                6                6.1
<350           52 (36.1)       45   (87)                8             17.8
≥350           92        74   (80)                4                 5.4
<500           93 (64.6)       77   (83)              10            13.0
≥500           51        42   (82)                2                 4.8
*Two of the 146 CD4 counts could not be traced.
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